Literature DB >> 11973411

Chronic and acute effects of dronedarone on the action potential of rabbit atrial muscle preparations: comparison with amiodarone.

Wei Sun1, Jonnalagedda S M Sarma, Bramah N Singh.   

Abstract

Dronedarone, a noniodinated derivative of amiodarone, is under evaluation as a potentially less toxic anti-arrhythmic alternative to amiodarone. The acute and chronic electrophysiologic effects of dronedarone and amiodarone were compared in isolated rabbit atrial muscle by microelectrode techniques. Four-week PO treatment with dronedarone or amiodarone increased action potential duration (APD90) (58 +/- 4 ms control versus 69 +/- 2 ms dronedarone, p < 0.01; 68 +/- 3 ms amiodarone, p < 0.01 for a 100-mg/kg/d dose) and effective refractory period (49 +/- 6 ms control versus 68 +/- 4 ms dronedarone, p < 0.01; 63 +/- 3 ms amiodarone, p < 0.01). The APD90 prolonged reverse rate-dependency. In contrast, acute superfusion with 10 microM dronedarone or amiodarone decreased APD90 (61 +/- 6 ms control versus 53 +/- 4 ms dronedarone, p < 0.05; 52 +/- 6 ms amiodarone, p < 0.05), effective refractory period (50 +/- 5 ms control versus 44 +/- 4 ms dronedarone, p < 0.05; 43 +/- 6 ms amiodarone, p < 0.05), and the maximum upstroke slope of the action potential (Vmax) (188 +/- 9 V/s control versus 182 +/- 11 V/s dronedarone p < 0.05; 182 +/- 11 V/s amiodarone, p < 0.05). Thus, chronic and acute electrophysiologic effects of dronedarone on rabbit atrial muscle are similar to those of amiodarone, suggesting a similar potential against atrial arrhythmias.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11973411     DOI: 10.1097/00005344-200205000-00008

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  26 in total

1.  Effect of dronedarone on Na+, Ca2+ and HCN channels.

Authors:  Roman Bogdan; Heinz Goegelein; Hartmut Ruetten
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2011-01-29       Impact factor: 3.000

Review 2.  Mechanisms of antiarrhythmic drug actions and their clinical relevance for controlling disorders of cardiac rhythm.

Authors:  Uma Srivatsa; Nitin Wadhani; Bramah N Singh
Journal:  Curr Cardiol Rep       Date:  2002-09       Impact factor: 2.931

3.  Acute dronedarone is inferior to amiodarone in terminating and preventing atrial fibrillation in canine atria.

Authors:  Alexander Burashnikov; Luiz Belardinelli; Charles Antzelevitch
Journal:  Heart Rhythm       Date:  2010-05-15       Impact factor: 6.343

Review 4.  Atrial fibrillation and heart failure in the elderly.

Authors:  Pedram Kazemian; Gavin Oudit; Bodh I Jugdutt
Journal:  Heart Fail Rev       Date:  2012-09       Impact factor: 4.214

Review 5.  Benefit-risk assessment of dronedarone in the treatment of atrial fibrillation.

Authors:  Ahmed M A Adlan; Gregory Y H Lip
Journal:  Drug Saf       Date:  2013-02       Impact factor: 5.606

6.  Acute effects of dronedarone on both components of the cardiac delayed rectifier K+ current, HERG and KvLQT1/minK potassium channels.

Authors:  Dierk Thomas; Sven Kathofer; Wei Zhang; Kezhong Wu; Anna-Britt Wimmer; Edgar Zitron; Volker A W Kreye; Hugo A Katus; Wolfgang Schoels; Christoph A Karle; Johann Kiehn
Journal:  Br J Pharmacol       Date:  2003-09-29       Impact factor: 8.739

7.  Potent antiarrhythmic effects of chronic amiodarone in canine pulmonary vein sleeve preparations.

Authors:  Serge Sicouri; Luiz Belardinelli; Leif Carlsson; Charles Antzelevitch
Journal:  J Cardiovasc Electrophysiol       Date:  2009-02-27

Review 8.  [Dronedarone: the new antiarrythmic agent?].

Authors:  J Brachmann; A-M Sinha
Journal:  Herzschrittmacherther Elektrophysiol       Date:  2009-06

Review 9.  Novel approaches for pharmacological management of atrial fibrillation.

Authors:  Joachim R Ehrlich; Stanley Nattel
Journal:  Drugs       Date:  2009       Impact factor: 9.546

10.  Recent advances in pharmacotherapy of atrial fibrillation.

Authors:  J Singh; J S Braich
Journal:  Indian J Pharmacol       Date:  2009-08       Impact factor: 1.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.